Aequus Pharmaceuticals Inc. reported revenue results for the first quarter ended March 31, 2017. The company recorded revenue of CAD 293,002 in the first quarter of 2017 compared to CAD 116,083 in the first quarter of 2016, representing a growth of 152% when comparing the two quarters.

Revenues are expected to continue to grow in the current year as these products continue to penetrate market share held by the branded equivalents and similar medications within the class, along with new prescription products that Aequus is currently negotiating for the Canadian market. Sales levels are expected to be inconsistent and unpredictable over the next twelve months as reimbursement activities and inventory stock-up occurs for each product.